This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cramer's 'Mad Money' Recap: Focus on Making Money

Cramer was bearish on Alcoa (AA).

Cancer Treatment Breakthrough?

In his second "Executive Decision" segment, Cramer sat down with Daniel Junius, president and CEO of ImmunoGen (IMGN - Get Report), a speculative biotech developing the next generation of cancer-fighting drugs. ImmunoGen just received Food and Drug Administration approval for its latest breast cancer drug, T-DM1.

Junius said T-DM1 is a big breakthrough in breast cancer treatments and the drug should be available to patients within the next two weeks. He said it's exciting for both its therapeutic value but also because it will provide ImmunoGen a steady revenue stream for its other drugs in the pipeline.

Among those other drugs are IMGN-853, which is in early-stage testing to treat ovarian cancer, and IMGN-901, to treat small-cell lung cancer. Junius said the 853 is an important compound for the company and could lead to other indications, while 901 is showing encouraging results in prolonging life where there hasn't been any new treatments in 25 years.

Junius also stressed the importance of these early-stage trials. He explained that time is money for the company, so getting patients into studies quickly allows them to make important go or no-go decision early so they can focus on only the most promising compounds.

Cramer called ImmunoGen one of the least hyped but still most important speculative biotech news out there for investors.

No Huddle Offense

In his "No Huddle Offense" segment, Cramer posed this question: Have hedge funds become too powerful? He said David Einhorn suing Apple (AAPL) over its cash hoards is just the tip of the iceberg. Other activist investors have taken aim at Herbalife (HLF), Hain Celestial (HAIN) and Yahoo! (YHOO), among countless others.

Cramer said that Apple has soared 6,300% over the past decade -- doesn't that give the company some benefit of the doubt? He said Einhorn needs to accept Apple for what it is -- the company is only playing by the rules and, in the end, shareholders have little to gain from his proposals.

Cramer said these activist actions are far less about doing good for shareholders as they are ways for hedge funds to prop up their performance. These guys need to admit they were wrong and just sell their positions, he concluded.

To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

-- Written by Scott Rutt in Washington, D.C.

To email Scott about this article, click here: Scott Rutt

Follow Scott on Twitter @ScottRutt or get updates on Facebook, ScottRuttDC
At the time of publication, Cramer's Action Alerts PLUS had a position in AAPL, ETN, HD and SLB.

Jim Cramer, host of the CNBC television program "Mad Money," is a Markets Commentator for, Inc., and CNBC, and a director and co-founder of All opinions expressed by Mr. Cramer on "Mad Money" are his own and do not reflect the opinions of or its affiliates, or CNBC, NBC Universal or their parent company or affiliates. Mr. Cramer's opinions are based upon information he considers to be reliable, but neither, nor CNBC, nor either of their affiliates and/or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such. Mr. Cramer's statements are based on his opinions at the time statements are made, and are subject to change without notice. No part of Mr. Cramer's compensation from CNBC or is related to the specific opinions expressed by him on "Mad Money."

None of the information contained in "Mad Money" constitutes a recommendation by Mr. Cramer, or CNBC that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the program. Mr. Cramer's past results are not necessarily indicative of future performance. Neither Mr. Cramer, nor, nor CNBC guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the program. The strategy or investments discussed may fluctuate in price or value and you may get back less than you invested. Before acting on any information contained in the program, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.

Some of the stocks mentioned by Mr. Cramer on "Mad Money" are held in Mr. Cramer's Action Alerts PLUS Portfolio. When that is the case, appropriate disclosure is made on the program and in the "Mad Money" recap available on The Action Alerts PLUS Portfolio contains all of Mr. Cramer's personal investments in publicly-traded equity securities only, and does not include any mutual fund holdings or other institutionally managed assets, private equity investments, or his holdings in, Inc. Since March 2005, the Action Alerts PLUS Portfolio has been held by a Trust, the realized profits from which have been pledged to charity. Mr. Cramer retains full investment discretion with respect to all securities contained in the Trust. Mr. Cramer is subject to certain trading restrictions, and must hold all securities in the Action Alerts PLUS Portfolio for at least one month, and is not permitted to buy or sell any security he has spoken about on television or on his radio program for five days following the broadcast.
3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AMZN $493.93 2.50%
CRZO $25.05 0.20%
HD $114.99 0.99%
IMGN $7.23 1.40%
KORS $50.64 0.82%


Chart of I:DJI
DOW 16,040.57 +26.19 0.16%
S&P 500 1,862.09 +9.88 0.53%
NASDAQ 4,313.7060 +44.9430 1.05%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs